Robert Fenstermaker
Chief Medical Officer, MimiVax, Inc. · University at Buffalo School of Medicine
Credentials: · · ·
History
1987–1989- 1981–1987
Neurological Surgery
1977–1981
Research
PLoS ONE · 2012 · 173 citations
NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017
Journal of the National Comprehensive Cancer Network · 2017 · 168 citations
Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells
Cancer Research · 2006 · 149 citations
- AF
20 papers · 2 as a resident
18 papers
- RP
15 papers
15 papers
- JQ
14 papers
- LL
12 papers · 1 as a resident
- VG
12 papers
- NA
10 papers · 2 as a resident
Grants
- 2006–2008
Immunotherapy for Gliomas with Monoclonal Antibodies Targeting MCSP
National Institute of Neurological Disorders and Stroke · R21
Contact PI · $441.5K · Roswell Park Cancer Institute Corp
- 2004–2007
Targeting the Anti-Apoptotic Protein Survivin in Glioma
National Institute of Neurological Disorders and Stroke · R21
Contact PI · $470.3K · Roswell Park Cancer Institute Corp
Clinical trials
- 2023–2026
Principal investigator · Unknown · Phase 1
Photolitec LLC
- 2021–2024
SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Principal investigator · Unknown · Phase 2
MimiVax, LLC
- 2015–2026
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Principal investigator · Active not recruiting · Phase 2
Roswell Park Cancer Institute
- 2012–2014
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
Principal investigator · Completed · Phase 1
Roswell Park Cancer Institute